The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Spanish biotech Mundipharma Biologics S.L.’s biosimilar to Amgen’s (NASDAQ:AMGN) Neulasta (pegfilgrastim).
A final decision from the European Commission usually takes ~60 days
https://seekingalpha.com/news/3506860-european-advisory-group-backs-biosimilar-amgens-neulasta
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.